Academic Journal

Oral octanoylcarnitine alleviates exercise intolerance in mouse models of long-chain fatty acid oxidation disorders.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Oral octanoylcarnitine alleviates exercise intolerance in mouse models of long-chain fatty acid oxidation disorders.
Συγγραφείς: Solo KJ; Department of Pediatrics, Division of Genetic and Genomic Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Zhang Y; Department of Pediatrics, Division of Genetic and Genomic Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Bharathi SS; Department of Pediatrics, Division of Genetic and Genomic Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Zhang BB; Department of Pediatrics, Division of Genetic and Genomic Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Richert AC; Department of Pediatrics, Division of Genetic and Genomic Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Schmidt AV; Department of Pediatrics, Division of Genetic and Genomic Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Van't Land C; Department of Pediatrics, Division of Genetic and Genomic Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., D'Annibale O; Department of Pediatrics, University of Colorado Anschutz Medical Campus/Children's Hospital of Colorado, Aurora, Colorado, USA., Wood TC; Department of Pediatrics, University of Colorado Anschutz Medical Campus/Children's Hospital of Colorado, Aurora, Colorado, USA., Goetzman ES; Department of Pediatrics, Division of Genetic and Genomic Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Πηγή: JCI insight [JCI Insight] 2025 Oct 16; Vol. 10 (22). Date of Electronic Publication: 2025 Oct 16 (Print Publication: 2025).
Τύπος έκδοσης: Journal Article; Research Support, N.I.H., Extramural
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: eCollection Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE
Imprint Name(s): Original Publication: Ann Arbor, Michigan : American Society for Clinical Investigation, [2016]-
Ιατρικοί όροι (MeSH): Carnitine*/analogs & derivatives , Carnitine*/administration & dosage , Carnitine*/pharmacology , Fatty Acids*/metabolism , Lipid Metabolism, Inborn Errors*/drug therapy , Lipid Metabolism, Inborn Errors*/metabolism , Exercise Tolerance*/drug effects, Muscle, Skeletal/metabolism ; Muscle, Skeletal/drug effects ; Carnitine O-Acetyltransferase/metabolism ; Myocardium/metabolism ; Animals ; Mice ; Disease Models, Animal ; Oxidation-Reduction ; Administration, Oral ; Male ; Triglycerides ; Mice, Inbred C57BL
Περίληψη: Long-chain fatty acid oxidation disorders (LC-FAODs) cause energy deficits in heart and skeletal muscle that are only partially corrected by current medium-chain lipid therapies such as triheptanoin. We find that heart and muscle lack medium-chain acyl-CoA synthetases, limiting the capacity for β-oxidation of medium-chain fatty acids. Instead, heart and muscle mitochondria robustly respire on medium-chain acylcarnitines. The mitochondrial matrix enzyme carnitine acetyltransferase (CrAT) efficiently converts orally delivered octanoylcarnitine (C8-carnitine) to octanoyl-CoA for energy generation. C8-carnitine exhibits twice the oral bioavailability of triheptanoin and distributes to muscle and heart. A single oral dose significantly enhances grip strength and treadmill endurance while attenuating lactic acidosis in 2 mouse models of LC-FAODs. Thus, medium-chain acylcarnitines overcome a previously unrecognized metabolic bottleneck in LC-FAOD muscle and may represent an alternative to triglyceride-based therapies for bioenergetic disorders.
Σχόλια: Update of: bioRxiv. 2025 Jun 25:2025.06.24.661304. doi: 10.1101/2025.06.24.661304.. (PMID: 40667310)
References: Mol Genet Metab. 2006 Sep-Oct;89(1-2):58-63. (PMID: 16876451)
PLoS One. 2015 Mar 11;10(3):e0116587. (PMID: 25760036)
Am J Physiol Endocrinol Metab. 2006 Oct;291(4):E860-6. (PMID: 16705058)
Anal Biochem. 2019 Sep 15;581:113332. (PMID: 31194945)
Nutrients. 2024 Aug 14;16(16):. (PMID: 39203843)
touchREV Endocrinol. 2021 Nov;17(2):108-111. (PMID: 35118456)
Am J Physiol Renal Physiol. 2020 Oct 1;319(4):F603-F611. (PMID: 32830538)
J Inherit Metab Dis. 2023 Sep;46(5):848-873. (PMID: 37530674)
Mol Genet Metab. 2024 May;142(1):108350. (PMID: 38458123)
Biochim Biophys Acta. 2013 Jun;1832(6):773-9. (PMID: 23485643)
Lab Invest. 2009 Dec;89(12):1348-54. (PMID: 19736549)
Mov Disord. 2024 Aug;39(8):1386-1396. (PMID: 38725190)
Mol Genet Metab. 2023 Nov;140(3):107689. (PMID: 37660571)
Am J Physiol Endocrinol Metab. 2010 Feb;298(2):E362-71. (PMID: 19903863)
J Biol Chem. 1981 Oct 10;256(19):9861-8. (PMID: 7275984)
Cell Rep. 2020 Nov 10;33(6):108374. (PMID: 33176143)
Sci Rep. 2020 Oct 27;10(1):18367. (PMID: 33110171)
Mol Genet Metab. 2015 Dec;116(4):260-8. (PMID: 26547562)
Pediatr Clin North Am. 2018 Apr;65(2):317-335. (PMID: 29502916)
Mol Cell Proteomics. 2013 Jun;12(6):1709-22. (PMID: 23436904)
Pharmacol Rev. 2022 Jul;74(3):506-551. (PMID: 35710135)
Eur J Biochem. 1996 Dec 1;242(2):186-90. (PMID: 8973631)
Hum Mol Genet. 2023 Jul 4;32(14):2347-2356. (PMID: 37162351)
J Biol Chem. 1985 Jan 25;260(2):1326-37. (PMID: 3968064)
FASEB J. 2018 Jun 22;:fj201800634R. (PMID: 29932868)
Clin Chim Acta. 1994 Sep;229(1-2):99-106. (PMID: 7988059)
J Appl Physiol (1985). 2006 Jan;100(1):76-82. (PMID: 16141384)
Diabetes. 2019 Apr;68(4):819-831. (PMID: 30728184)
N Engl J Med. 1969 May 8;280(19):1045-58. (PMID: 4888178)
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15592-7. (PMID: 9861014)
Hum Mol Genet. 2001 Sep 15;10(19):2069-77. (PMID: 11590124)
J Biol Chem. 2009 Oct 9;284(41):27799-27807. (PMID: 19666922)
J Biol Chem. 2023 Feb;299(2):102848. (PMID: 36587768)
Mol Genet Metab. 2023 Jun;139(2):107605. (PMID: 37207470)
J Inherit Metab Dis. 2023 Sep;46(5):943-955. (PMID: 37276053)
J Clin Invest. 2002 Jul;110(2):259-69. (PMID: 12122118)
PLoS One. 2015 Mar 09;10(3):e0119479. (PMID: 25751285)
J Clin Invest. 2024 Apr 30;134(12):. (PMID: 38687608)
Am J Physiol Gastrointest Liver Physiol. 2023 Oct 1;325(4):G287-G294. (PMID: 37461880)
Psychosom Med. 2018 Feb/Mar;80(2):154-159. (PMID: 29076953)
Biochim Biophys Acta. 2009 Aug;1791(8):806-15. (PMID: 19465148)
J Inherit Metab Dis. 2010 Jun;33(3):237-46. (PMID: 20446112)
Cell Rep. 2017 Jul 18;20(3):655-667. (PMID: 28723568)
Mol Genet Metab. 2023 Jan;138(1):106982. (PMID: 36580829)
Cardiol Young. 2025 Jan;35(1):218-220. (PMID: 39780480)
J Biol Chem. 2001 Sep 21;276(38):35961-6. (PMID: 11470804)
Mol Genet Metab. 2017 Apr;120(4):370-377. (PMID: 28189603)
Biochem Biophys Res Commun. 2006 Aug 4;346(3):974-80. (PMID: 16781677)
Clin Pharmacol Drug Dev. 2021 Nov;10(11):1325-1334. (PMID: 33789001)
Orphanet J Rare Dis. 2017 Oct 2;12(1):160. (PMID: 28969699)
Biochim Biophys Acta. 1987 Jun 22;924(3):530-42. (PMID: 3593765)
Ann Hepatol. 2013 Sep-Oct;12(5):803-9. (PMID: 24018499)
Cell Metab. 2012 May 2;15(5):764-77. (PMID: 22560225)
Cell Rep. 2016 Jun 28;16(1):201-212. (PMID: 27320917)
Int Dairy J. 2006 Nov;16(11):1262-1271. (PMID: 32288340)
Ann Clin Transl Neurol. 2019 Oct;6(10):1949-1960. (PMID: 31520525)
J Inherit Metab Dis. 1999 Jun;22(4):488-502. (PMID: 10407781)
Neuromuscul Disord. 2022 Apr;32(4):295-304. (PMID: 35241345)
Mol Genet Metab. 2012 Jan;105(1):110-5. (PMID: 22030098)
Grant Information: R01 DK090242 United States DK NIDDK NIH HHS
Contributed Indexing: Keywords: Bioenergetics; Genetics; Metabolism; Monogenic diseases; Therapeutics
Substance Nomenclature: S7UI8SM58A (Carnitine)
0 (Fatty Acids)
S1HB7P0O16 (octanoylcarnitine)
EC 2.3.1.7 (Carnitine O-Acetyltransferase)
0 (Triglycerides)
2P6O7CFW5K (triheptanoin)
Entry Date(s): Date Created: 20251016 Date Completed: 20251124 Latest Revision: 20260902
Update Code: 20260902
PubMed Central ID: PMC12643506
DOI: 10.1172/jci.insight.199443
PMID: 41100184
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:2379-3708
DOI:10.1172/jci.insight.199443